Sutro Biopharma, Inc. (STRO)

Market Cap	63.95M
Revenue (ttm)	62.04M
Net Income (ttm)	-227.46M
Shares Out	83.78M
EPS (ttm)	-2.96
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	957,630
Open	0.770
Previous Close	0.770
Day's Range	0.757 - 0.797
52-Week Range	0.758 - 6.130
Beta	1.22
Analysts	Buy
Price Target	6.83 (+794.68%)
Earnings Date	Mar 13, 2025

About STRO

Sutro Biopharma, Inc. operates as a oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. The company also develops VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in P...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 27, 2018
• Employees: 310
• Stock Exchange: NASDAQ
• Ticker Symbol: STRO
• Website: https://www.sutrobio.com

Financial Performance

In 2024, Sutro Biopharma's revenue was $62.04 million, a decrease of -59.64% compared to the previous year's $153.73 million. Losses were -$227.46 million, 113.0% more than in 2023.

Analyst Forecast

According to 7 analysts, the average rating for STRO stock is "Buy." The 12-month stock price forecast is $6.83, which is an increase of 794.68% from the latest price.

Price Target

$6.83

(794.68% upside)

Analyst Consensus: Buy